Paul R. Edick
Chairman & Chief Executive Officer
Paul R. Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017. Prior to Xeris, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis PLC, now Allergan PLC, in November 2014. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive Officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006 after having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business and the development of a clinical stage portfolio, and the company was subsequently sold to Meda AB of Sweden in 2007.
Mr. Edick also possesses extensive industry experience with leading consumer, pharmaceutical, and healthcare organizations, including Pharmacia as Group Vice President and President, Asia Pacific & Latin America Operations; and Searle Pharmaceuticals as President of Asia Pacific, Canada, and Latin America Operations and VP, Canada and Latin America Operations. He also led the national Managed Care and Marketing units, as well as the Global Pain & Inflammation unit, which included the commercialization and launch planning, for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising, and advisory positions in Procter & Gamble, Ortho Pharmaceuticals, and The Hamilton Group.
Mr. Edick has previously served on a number of pharmaceutical and healthcare company boards, including Milestone Pharmaceuticals Inc., Iterum Therapeutics (Nasdaq: ITRM), PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals PLC (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications.
Mr. Edick holds a BA in psychology from Hamilton College.
Mr. Edick also possesses extensive industry experience with leading consumer, pharmaceutical, and healthcare organizations, including Pharmacia as Group Vice President and President, Asia Pacific & Latin America Operations; and Searle Pharmaceuticals as President of Asia Pacific, Canada, and Latin America Operations and VP, Canada and Latin America Operations. He also led the national Managed Care and Marketing units, as well as the Global Pain & Inflammation unit, which included the commercialization and launch planning, for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising, and advisory positions in Procter & Gamble, Ortho Pharmaceuticals, and The Hamilton Group.
Mr. Edick has previously served on a number of pharmaceutical and healthcare company boards, including Milestone Pharmaceuticals Inc., Iterum Therapeutics (Nasdaq: ITRM), PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals PLC (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications.
Mr. Edick holds a BA in psychology from Hamilton College.